Michelle E A Borm

891 citations
25 papers · 465 · h-index 11

Impact in

Papers in

  • Rheumatology 16
    • Rheumatoid Arthritis Research and Therapies 16
  • Genetics 4
    • Inflammatory Bowel Disease 4
    • Chronic Lymphocytic Leukemia Research 3
Co-authors
Chris J. Mulder (3 shared papers)Adriaan A. van Bodegraven (2 shared papers)Georg Kraal (2 shared papers)Markus W. Büchler (1 shared paper)Luca Degrate (1 shared paper)Moritz N. Wente (1 shared paper)Ulf Hinz (1 shared paper)Thilo Welsch (1 shared paper)
Journals
Annals of the Rheumatic Diseases (8 papers)Lara D. Veeken (3 papers)Arthritis Research & Therapy (2 papers)Gastroenterology (2 papers)Arthritis Care & Research (1 paper)
Partner nations
NetherlandsSwitzerlandGermany

In The Last Decade

Michelle E A Borm

25 papers receiving 453 citations

Peers

Michelle E A Borm
Comparison fields: 5 of 61
  • Rheumatology 115
  • Gastroenterology 25
  • Immunology 87
  • Oncology 97
  • Hematology 33
Replace Avery Maddox with:
Avery Maddox United States
Rie Masai Japan
H.E. Blum Germany
Eun Suk Kang South Korea
Camilla Vassallo Italy
H. Jouhadi Morocco
Chiara Quarneti Italy
Ray Lonsdale United Kingdom
Alexander I. Aspinall Canada
F P Ryan United Kingdom
Michelle E A Borm relative to Avery Maddox United States Avery Maddox's profile →
Citations per field
00.5×2×4×5.5×
Avery Maddox · 1×
Citations per year

Countries citing papers authored by Michelle E A Borm

Since Specialization
Citations

This map shows the geographic impact of Michelle E A Borm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle E A Borm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle E A Borm more than expected).

Fields of papers citing papers by Michelle E A Borm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle E A Borm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle E A Borm. The network helps show where Michelle E A Borm may publish in the future.

Co-authors

The 25 scholars most cited alongside Michelle E A Borm, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michelle E A Borm Line = papers co-authored together Michelle E A Borm links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Evaluation of the International Study Group of Pancreatic Surgery definition of delayed gastric emptying after pancreatoduodenectomy in a high-volume centre
British journal of surgery ·Thilo Welsch, Michelle E A Borm, Luca Degrate, Ulf Hinz, Markus W. Büchler, Moritz N. Wente
2010112
2
A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis
International Journal of Immunogenetics ·Michelle E A Borm, Adriaan A. van Bodegraven, Chris J. Mulder, Georg Kraal, (unknown)
200571
3
The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype
Genes and Immunity ·Michelle E A Borm, Adriaan A. van Bodegraven, Chris J. Mulder, Georg Kraal, (unknown)
200838
4
Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors
Annals of the Rheumatic Diseases ·Xavier M Teitsma, Johannes W. G. Jacobs, Paco M J Welsing, Pascal H P de Jong, Johanna M. W. Hazes, A. Weel, Attila Pethö‐Schramm, Michelle E A Borm, Jacob M. van Laar, Floris P. J. G. Lafeber, J. W. J. Bijlsma
201835
5
A major quantitative trait locus on mouse chromosome 3 is involved in disease susceptibility in different colitis models
Gastroenterology ·Michelle E A Borm, Jianping He, Brian L. Kelsall, A. S. Peña, Warren Strober, Gerd Bouma
200535
6
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology
Arthritis Research & Therapy ·Xavier M Teitsma, Wei Yang, Johannes W. G. Jacobs, Attila Pethö‐Schramm, Michelle E A Borm, Amy C. Harms, Thomas Hankemeier, Jacob M. van Laar, J. W. J. Bijlsma, Floris P. J. G. Lafeber
201829
7
Severity of COVID-19 and adverse long-term outcomes: a retrospective cohort study based on a US electronic health record database
BMJ Open ·Nick Jovanoski, Xin Chen, Ursula Becker, Kelly A. Zalocusky, Devika Chawla, Larry Tsai, Michelle E A Borm, Margaret Neighbors, Vincent Yau
202123
8
IL12B and IRF1 gene polymorphisms and susceptibility to celiac disease
European Journal of Immunogenetics ·Diana Seegers, Michelle E A Borm, Martine J. van Belzen, Chris J. Mulder, J. Bailing, J. Bart A. Crusius, Jos W. R. Meijer, Cisca Wijmenga, A. S. Peña, (unknown)
200323
9
Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials
Annals of the Rheumatic Diseases ·Maxime M. A. Verhoeven, Marjolein JH de Hair, Janneke Tekstra, J. W. J. Bijlsma, Jacob M. van Laar, Attila Pethoe-Schramm, Michelle E A Borm, Evert-Jan ter Borg, Suzanne P. Linn-Rasker, Xavier M Teitsma, Floris P. J. G. Lafeber, Johannes W. G. Jacobs, Paco M J Welsing
201915
10
Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy
Arthritis Research & Therapy ·Xavier M Teitsma, Johannes W. G. Jacobs, Michal Mokrý, Michelle E A Borm, Attila Pethö‐Schramm, Jacob M. van Laar, J. W. J. Bijlsma, Floris P. J. G. Lafeber
201714
11
Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies
Lara D. Veeken ·Xavier M Teitsma, Johannes W. G. Jacobs, Paco M J Welsing, Attila Pethö‐Schramm, Michelle E A Borm, Jacob M. van Laar, Floris P. J. G. Lafeber, J. W. J. Bijlsma
201714
12
Animal models of inflammatory bowel disease
Drug Discovery Today Disease Models ·Michelle E A Borm, Gerd Bouma
200410
13
Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate
Lara D. Veeken ·Maxime M. A. Verhoeven, Janneke Tekstra, Paco M J Welsing, Attila Pethö‐Schramm, Michelle E A Borm, George A W Bruyn, Reinhard Bos, E. N. Griep, Ruth Klaasen, Jacob M. van Laar, Floris P. J. G. Lafeber, J. W. J. Bijlsma, Marjolein J.H. de Hair, Johannes W G Jacobs
20197
14
Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy
Lara D. Veeken ·Xavier M Teitsma, Johannes W. G. Jacobs, Paco M J Welsing, Attila Pethö‐Schramm, Michelle E A Borm, Lidy Hendriks, N. H. A. M. Denissen, Jacob M. van Laar, Floris P. J. G. Lafeber, J. W. J. Bijlsma
20177
15
SAT0169 No evidence that concomitant glucocorticoid therapy affects efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trials
Annals of the Rheumatic Diseases ·M. Safy, J. W. G. Jacobs, M Edwardes, Jinglan Pei, M. De Hair, Xavier M Teitsma, Paco M J Welsing, Michelle E A Borm, Yves Luder, JM van Laar, Attila Pethö‐Schramm, J. W. J. Bijlsma
20186
16
Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.
PubMed ·Xavier M Teitsma, Johannes W G Jacobs, Arno N. Concepcion, Attila Pethö‐Schramm, Michelle E A Borm, Jacob M. van Laar, J. W. J. Bijlsma, Floris P. J. G. Lafeber
20195
17
Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis
The Journal of Rheumatology ·Maxime M. A. Verhoeven, Janneke Tekstra, Jacob M. van Laar, Attila Pethö‐Schramm, Michelle E A Borm, J. W. J. Bijlsma, Johannes W. G. Jacobs, Floris P. J. G. Lafeber, Paco M J Welsing
20204
18
Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab
PLoS ONE ·Xavier M Teitsma, Jenny Devenport, Johannes W. G. Jacobs, Attila Pethö‐Schramm, Michelle E A Borm, Petra Budde, J. W. J. Bijlsma, Floris P. J. G. Lafeber
20204
19
OP0033 Rapid and Sustained Remission in Early Rheumatoid Arthritis (RA) Treated to Target with Tocilizumab, Methotrexate, or their Combination: The U-Act-Early Strategy Study
Annals of the Rheumatic Diseases ·J. W. J. Bijlsma, Paco M J Welsing, Thasia Woodworth, Leonie M. Middelink, Corrado Bernasconi, Michelle E A Borm, F.P. Lafeber, Johannes W. G. Jacobs
20154
20
Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials
Arthritis Care & Research ·Maxime M. A. Verhoeven, Janneke Tekstra, Johannes W. G. Jacobs, J. W. J. Bijlsma, Jacob M. van Laar, Attila Pethö‐Schramm, Michelle E A Borm, Floris P. J. G. Lafeber, Paco M J Welsing
20203

About Michelle E A Borm

Michelle E A Borm is a scholar working on Rheumatology, Genetics, Immunology, Genetics and Cancer Research, having authored 25 papers that have together received 465 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (16 papers), Inflammatory Bowel Disease (4 papers), NF-κB Signaling Pathways (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Acute Lymphoblastic Leukemia research (2 papers), Helicobacter pylori-related gastroenterology studies (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Immune Response and Inflammation (2 papers). The work is most often cited by research in Rheumatology (115 citations), Gastroenterology (25 citations), Immunology (87 citations), Oncology (97 citations) and Hematology (33 citations). Michelle E A Borm has collaborated with scholars based in Netherlands, Switzerland and Germany. Frequent co-authors include Chris J. Mulder, Adriaan A. van Bodegraven, Georg Kraal, Markus W. Büchler, Luca Degrate, Moritz N. Wente, Ulf Hinz, Thilo Welsch, J. W. J. Bijlsma and Attila Pethö‐Schramm. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, Arthritis Research & Therapy, Gastroenterology and Arthritis Care & Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Avery MaddoxBreakdown of academic impact, for papers by Rie MasaiBreakdown of academic impact, for papers by H.E. BlumBreakdown of academic impact, for papers by Eun Suk KangBreakdown of academic impact, for papers by Camilla VassalloBreakdown of academic impact, for papers by H. JouhadiBreakdown of academic impact, for papers by Chiara QuarnetiBreakdown of academic impact, for papers by Ray LonsdaleBreakdown of academic impact, for papers by Alexander I. AspinallBreakdown of academic impact, for papers by F P Ryan